Swati Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Swati Patel has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Arati Saptarshi
Department of Haematogenetics, ICMR-National Institute of Immunohematology, Indian Council of Medical Research, Mumbai, India
1 shared publication - Archana Swami
Department of Pediatric Hemato-Oncology, Bai Jerbai Wadia Hospital for Children, Mumbai, Maharashtra, India
1 shared publication - Bageshree Seth1 shared publication
Govind Choudhary
1 shared publication- Mukul Aggarwal
Department of Hematology, AIIMS, New Delhi, India
1 shared publication Nida Mirza
1 shared publication
Latest Publications
- Open Access
- 17 November 2026
- Published by Springer Nature in Scientific Reports
SEC23B variants and mRNA expression defects in congenital dyserythropoietic anaemia type II: comprehensive analysis in an Indian cohort
- 17 November 2026
- Published by Springer Nature in Scientific Reports
Open AccessSEC23B variants and mRNA expression defects in congenital dyserythropoietic anaemia type II: comprehensive analysis in an Indian cohort
- Open Access
- 2 January 2024
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 9 (1) , 28-31
Secondary hemophagocytic lymphohistiocytosis in a child with Sickle Cell Anemia and Hepatitis A and Hepatitis E co-infection: A case report
- 2 January 2024
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 9 (1) , 28-31
Open AccessSecondary hemophagocytic lymphohistiocytosis in a child with Sickle Cell Anemia and Hepatitis A and Hepatitis E co-infection: A case report
- Open Access
- 1 January 2023
- Published by Medknow in Indian Journal of Cancer
- Vol. 60 (1) , 134-139
Early response to chemotherapy in children with Langerhans cell histiocytosis predicts long-term disease-free survival
Background: Langerhans cell histiocytosis (LCH) is a rare clonal malignancy of the monocyte-macrophage system. Patients with lesions in “risk organs” have significantly higher risk of mortality than patients with lesions limited to “non-risk” sites. The influence of early response to therapy on long-term survival in this heterogeneous multi-system disease was analyzed. Methods: During a 7-year period, we retrospectively analyzed the findings in 24 consecutive patients who required systemic chemotherapy for LCH [single system with multifocal bone involvement and multisystem involvement with or without risk organ (RO) involvement]. All patients were started on vinblastine and prednisolone. Progressive disease was treated with salvage protocols or targeted therapy. Positron emission tomography-computed tomography (PET-CT)/conventional CT based response assessment was performed at week 6 of chemotherapy, and if needed after week 12 of chemotherapy. Results: MFO bone, MS ROneg, and MS ROpos LCH was observed in 3, 4, and 17 patients, respectively. Age range of patients varied from 1 month–7 years (median = 18 months). The EFS and OS were 100% and 100% for MFO bone, 50% and 100%, respectively, for MS ROneg and 35% and 52%, respectively, for MS ROpos. OS was 93% and 100% for CR attained at 6 and 12 weeks respectively regardless of the risk status (P < 0.01). Conclusion: Rapid early response, that is, complete remission at 6 and 12 weeks was associated with significantly improved overall survival. In slow responders, early salvage with alternative regimens or targeted therapy may result in better outcomes.
- 1 January 2023
- Published by Medknow in Indian Journal of Cancer
- Vol. 60 (1) , 134-139
Open AccessEarly response to chemotherapy in children with Langerhans cell histiocytosis predicts long-term disease-free survival
Background: Langerhans cell histiocytosis (LCH) is a rare clonal malignancy of the monocyte-macrophage system. Patients with lesions in “risk organs” have significantly higher risk of mortality than patients with lesions limited to “non-risk” sites. The influence of early response to therapy on long-term survival in this heterogeneous multi-system disease was analyzed. Methods: During a 7-year period, we retrospectively analyzed the findings in 24 consecutive patients who required systemic chemotherapy for LCH [single system with multifocal bone involvement and multisystem involvement with or without risk organ (RO) involvement]. All patients were started on vinblastine and prednisolone. Progressive disease was treated with salvage protocols or targeted therapy. Positron emission tomography-computed tomography (PET-CT)/conventional CT based response assessment was performed at week 6 of chemotherapy, and if needed after week 12 of chemotherapy. Results: MFO bone, MS ROneg, and MS ROpos LCH was observed in 3, 4, and 17 patients, respectively. Age range of patients varied from 1 month–7 years (median = 18 months). The EFS and OS were 100% and 100% for MFO bone, 50% and 100%, respectively, for MS ROneg and 35% and 52%, respectively, for MS ROpos. OS was 93% and 100% for CR attained at 6 and 12 weeks respectively regardless of the risk status (P < 0.01). Conclusion: Rapid early response, that is, complete remission at 6 and 12 weeks was associated with significantly improved overall survival. In slow responders, early salvage with alternative regimens or targeted therapy may result in better outcomes.